TransMedics Group (TMDX) Stock Price, News & Analysis

Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Key Stats

• Today's Range: $112.82 to $117.05
• 50-Day Range: $103.61 to $134.01
• 52-Week Range: $55.00 to $172.78
• Volume: 665,581 shs
• Average Volume: 998,422 shs
• Market Capitalization: $3.92 billion
• P/E Ratio: 59.57
• Dividend Yield: N/A
• Price Target: $123.00
• Consensus Rating: Moderate Buy

TransMedics Group Stock Analysis - MarketRank™

TransMedics Group scored higher than 66% of companies evaluated by MarketBeat, and ranked 348th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

TransMedics Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 43.00%

Earnings Growth

Earnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TransMedics Group is 59.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of TransMedics Group is 59.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27.

Price to Book Value per Share Ratio

TransMedics Group has a P/B Ratio of 12.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.19% of the float of TransMedics Group has been sold short.

Short Interest Ratio / Days to Cover

TransMedics Group has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in TransMedics Group has recently decreased by 4.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TransMedics Group does not currently pay a dividend.

Dividend Growth

TransMedics Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

24.19% of the float of TransMedics Group has been sold short.

Short Interest Ratio / Days to Cover

TransMedics Group has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in TransMedics Group has recently decreased by 4.12%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.08

News Sentiment

TransMedics Group has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for TransMedics Group this week, compared to 14 articles on an average week.

Search Interest

26 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.

MarketBeat Follows

6 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,903.00 in company stock.

Percentage Held by Insiders

Only 7.00% of the stock of TransMedics Group is held by insiders.

Percentage Held by Institutions

99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TMDX Stock Analysis - Frequently Asked Questions

How have TMDX shares performed this year?

TransMedics Group's stock was trading at $62.35 at the start of the year. Since then, TMDX stock has increased by 84.4% and is now trading at $114.96.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) issued its quarterly earnings results on Wednesday, July, 30th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.44. The company's revenue was up 37.7% on a year-over-year basis.
Read the conference call transcript.

When did TransMedics Group IPO?

TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Who are TransMedics Group's major shareholders?

TransMedics Group's top institutional investors include Geode Capital Management LLC (2.36%), Hood River Capital Management LLC (1.99%), Eventide Asset Management LLC (1.61%) and Marshall Wace LLP (1.60%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, Anil P Ranganath, David Weill, Edward M Basile, Stephanie Lovell and Laura Damme.
View institutional ownership trends.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 8/30/2025
• Next Earnings (Estimated): 10/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TMDX
• CIK: 1756262
• Web: www.transmedics.com
• Phone: (978) 552-0900
• Fax: N/A
• Employees: 210
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TransMedics Group: $123.00
• High Price Target: $150.00
• Low Price Target: $75.00
• Potential Upside/Downside: +7.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.93
• Trailing P/E Ratio: 59.57
• Forward P/E Ratio: 114.96
• P/E Growth: N/A
• Net Income: $35.46 million
• Net Margins: 13.49%
• Pretax Margin: 13.95%
• Return on Equity: 28.02%
• Return on Assets: 8.64%

Debt

• Debt-to-Equity Ratio: 1.61
• Current Ratio: 9.86
• Quick Ratio: 9.17

Sales & Book Value

• Annual Sales: $441.54 million
• Price / Sales: 8.88
• Cash Flow: $1.65 per share
• Price / Cash Flow: 69.87
• Book Value: $9.33 per share
• Price / Book: 12.32

Miscellaneous

• Outstanding Shares: 34,090,000
• Free Float: 31,704,000
• Market Cap: $3.92 billion
• Optionable: Optionable
• Beta: 2.09